|117.13||+3.14||+2.75%||Vol 2.11M||1Y Perf -45.33%|
|Dec 7th, 2023 16:00 DELAYED|
|0.37 0.32%||- -|
|Target Price||258.71||Analyst Rating||Hold 2.69|
|Potential %||120.87||Finscreener Ranking||★+ 44.07|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||+ 36.58|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★+ 43.55|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||18.81||Earnings Rating||Strong Sell|
|Market Cap||18.60B||Earnings Date||9th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||0.13|
|EPS Growth Next 5 Years %||22.20|
|Avg. Weekly Volume||2.95M|
|Avg. Monthly Volume||3.64M|
|Avg. Quarterly Volume||2.34M|
Illumina Inc. (NASDAQ: ILMN) stock closed at 117.13 per share at the end of the most recent trading day (a 2.75% change compared to the prior day closing price) with a volume of 2.11M shares and market capitalization of 18.60B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 7850 people. Illumina Inc. CEO is Francis A. DeSouza.
The one-year performance of Illumina Inc. stock is -45.33%, while year-to-date (YTD) performance is -42.07%. ILMN stock has a five-year performance of -63.56%. Its 52-week range is between 89 and 238.55, which gives ILMN stock a 52-week price range ratio of 18.81%
Illumina Inc. currently has a PE ratio of -7.60, a price-to-book (PB) ratio of 4.72, a price-to-sale (PS) ratio of 9.31, a price to cashflow ratio of 60.10, a PEG ratio of -0.34, a ROA of -34.58%, a ROC of -36.90% and a ROE of -52.89%. The company’s profit margin is -88.38%, its EBITDA margin is -78.20%, and its revenue ttm is $3.50 Billion , which makes it $22.26 revenue per share.
Of the last four earnings reports from Illumina Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.13 for the next earnings report. Illumina Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Illumina Inc. is Hold (2.69), with a target price of $258.71, which is +120.87% compared to the current price. The earnings rating for Illumina Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Illumina Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Illumina Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 18.30, ATR14 : 5.28, CCI20 : 135.05, Chaikin Money Flow : 0.22, MACD : -0.55, Money Flow Index : 66.37, ROC : 20.00, RSI : 59.93, STOCH (14,3) : 97.37, STOCH RSI : 1.00, UO : 67.93, Williams %R : -2.63), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Illumina Inc. in the last 12-months were: Aimee L. Hoyt (Option Excercise at a value of $0), Aimee L. Hoyt (Sold 4 788 shares of value $958 789 ), Alexander Aravanis (Option Excercise at a value of $0), Alexander Aravanis (Sold 5 398 shares of value $1 088 982 ), Charles E. Dadswell (Option Excercise at a value of $0), Dadswell Charles (Option Excercise at a value of $0), Francis A. DeSouza (Option Excercise at a value of $0), Hoyt Aimee (Option Excercise at a value of $0), Hoyt Aimee (Sold 5 103 shares of value $994 314 ), Joydeep Goswami (Option Excercise at a value of $0), Kathryne Gambrell Reeves (Option Excercise at a value of $0), Kevin Carl Pegels (Option Excercise at a value of $0), Phillip G. Febbo (Option Excercise at a value of $0), Reeves Kathryne (Option Excercise at a value of $0), Susan H. Tousi (Option Excercise at a value of $0), Susan H. Tousi (Sold 1 000 shares of value $208 075 ), Tousi Susan (Option Excercise at a value of $0), Tousi Susan (Sold 7 000 shares of value $1 434 570 ), TOUSI SUSAN H (Sold 500 shares of value $100 000 )
Mon, 16 Oct 2023 10:02 GMT Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), UnitedHealth (UNH) and BeiGene (BGNE)- TipRanks. All rights reserved.
Mon, 09 Oct 2023 18:51 GMT EU regulators to order Illumina to divest cancer test firm Grail, FT reports- TipRanks. All rights reserved.
Fri, 01 Sep 2023 13:55 GMT Early notable gainers among liquid option names on September 1st- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.